The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 29, 2023. Its latest SEC filing is a 15-12G from May 8, 2023.
10-K for FY2022, filed Mar 29, 2023
The sections below describe the company as of the FY2022 annual report.
Sells TZIELD and develops medicines and vaccines aimed at preventing or treating immune-mediated diseases including type one diabetes, lupus and celiac disease.
10-K for FY2022, filed Mar 29, 2023TZIELD (teplizumab-mzwv): a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years…View ↗
PRV-3279: a humanized bispecific scaffold molecule targeting the B-cell surface proteins, an inhibitory Fc receptor (“FcR”), known as…View ↗
ordesekimab: a human anti-interleukin 15 (“IL-15”) monoclonal antibody (“mAb”) for the treatment of gluten-free diet non-responsive celiac…View ↗
PRV-101: a CVB vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to…View ↗
Product revenues, net consists of net sales of TZIELD. The only performance obligation in the Company’s contracts with customers is to…View ↗
Distributors pay for TZIELD when it is delivered. Pharmaceutical partners pay for licenses and research and development work; Huadong payments track work performed, while Sanofi's upfront co-promotion payment is spread across its agreement period.
10-K for FY2022, filed Mar 29, 2023
$12.9M
10-K for FY2022, filed Mar 30, 2023
$12.9M ↗
TZIELD is sold through a specialty distributor and specialty pharmacies in the United States. Pharmaceutical companies also work with Provention under licensing, research and development, and co-promotion agreements.
10-K for FY2022, filed Mar 29, 2023
No. It lost $113.6M in FY2022.
10-K for FY2022, filed Mar 30, 2023
−$128.2MView ↗
10-K for FY2022, filed Mar 30, 2023
−$113.6MView ↗
10-K for FY2022, filed Mar 30, 2023
−$76.2MView ↗
8-K, filed Apr 27, 2023
At the effective time of the Merger (the “Effective Time”), each issued and outstanding Share (other than (i) Shares held in the treasury…View ↗
From development to sales
The older report described a clinical-stage company with no revenue; the latest describes a commercial-stage business shipping approved TZIELD while continuing to develop its pipeline.
10-K for FY2019, filed Mar 12, 2020 10-K for FY2022, filed Mar 29, 2023
Competes with Sanofi, Novo Nordisk, Eli Lilly, Medtronic, Abbott, Dexcom, Calypso, Equilium, Janssen, ImmunogenX, Takeda, Zedira, Dr. Falk, Anokion, Glaxo SmithKline, Roche, Aurinia Pharmaceuticals, Astra Zeneca, Selecta Biosciences, and Hansa Biopharma
10-K for FY2022, filed Mar 29, 2023The symptomatic treatment of T1D is a highly competitive market with large incumbents such as Sanofi, Novo Nordisk and Eli Lilly providing…View ↗
Loading...
